Rossen Donev received his PhD degree in 1999 from the Institute of Molecular Biology, Bulgarian Academy of Sciences. He did postdoctoral training at Imperial Cancer Research Fund, UK (renamed after the merger with Cancer Research Campaign to Cancer Research UK, London Research Institute) and Cardiff University. In 2007 he was awarded a New Investigator Grant Award from the Medical Research Council (UK) to establish himself as an independent Principle Investigator. In 2010 Dr. Donev was appointed Senior Lecturer at Swansea University. In 2016 Dr. Donev joined MicroPharm Ltd (UK) where currently he is Head of Research. He has published more than 60 research papers, chaired scientific meetings and given invited plenary talks. Rossen Donev has consulted on projects related to development of treatments for neurodevelopmental disorders and cancer therapies. He serves as Editor-in-Chief of the Advances in Protein Chemistry and Structural Biology and on editorial board of several other journals. His research interests include signaling pathways involved in neuropsychiatric disorders and tumor escape from the immune system, and development of therapeutic strategies for their treatment. More recently he has focused on development of immunotherapeutics for non-systemic applications.

• 1. Latest trends in structure based drug design with protein targetsAngshuman Bagchi2. From fragment- to peptide-protein interaction: addressing the structural basis of binding using Supervised Molecular Dynamics (SuMD)Stefano Moro3. Protein-protein and protein-ligand interactions: identification of potential inhibitors through computational analysisM. Michael Gromiha4. Aromatic-aromatic interactions in protein-drug and protein-protein interactionsAdrian Gustavo Turjanski5. Role of protein-protein interaction in allosteric drug design within the human methyltransferomeGuang Hu6. Protein-Protein Interactions as the Basis for Cyclin-Dependent Kinase InhibitionMark Klein7. Targeting FOXP3 complex ensemble in drug discoveryBin Li8. Targeting arrestin interactions with its partners for therapeutic purposesVsevolod V. Gurevich9. Protein interactomics in kidney stone researchVisith Thongboonkerd10. Human oral microbiome protein-protein interaction: a cross-talk with health systemic implicationsMarlene M.T. Barros11. Protein-protein complexes as targets for drug discovery against infectious diseasesYusuf Akhter12. Therapeutic intervention of protein-protein interactions in innate immunityKevin J. Lumb13. Physicochemical determinants of antibody-protein interactionsSibel Kalyoncu Uzunlar